A carregar...
Renal cancer resistance to antiangiogenic therapy is delayed by restoration of angiostatic signaling
Treatment of metastatic renal cell cancer (RCC) with antiangiogenic agents that block vascular endothelial growth factor (VEGF) receptor 2 signaling produces tumor regression in a substantial fraction of patients; however resistance typically develops within 6–12 months. The purpose of this study wa...
Na minha lista:
| Main Authors: | , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2010
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2956167/ https://ncbi.nlm.nih.gov/pubmed/20699227 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-10-0477 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|